Status:

RECRUITING

Partial Liver Segment 2/3 Transplantation Study

Lead Sponsor:

Oslo University Hospital

Conditions:

Colorectal Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

The patients will receive hepatectomy as a 2 stage procedure. In the first surgical procedure liver segments 2-3 are removed and liver donor segments 2-3 inserted. After growth of donor segments 2-3, ...

Eligibility Criteria

Inclusion

  • Histologically verified adenocarcinoma in colon/rectum.
  • Liver metastases, not amenable to liver resection
  • No signs of extra hepatic metastatic disease or local recurrence according to PET/CT scan within 4 weeks prior to the faculty meeting at the transplant unit, except patients may have 1-3 resectable lung lesions all\<15mm.
  • No signs of extra hepatic metastatic disease on CT thorax/abdomen/pelvis within 4 weeks prior to the faculty meeting at the transplant unit, except patients may have 1-3 resectable lung lesions all\<15mm.
  • No local recurrence according to MR-pelvis scan in patients with rectal cancer within 4 weeks prior to the faculty meeting at the transplant unit
  • No signs of local recurrence judged by colonoscopy / CT colography within 12 months prior to the faculty meeting at the transplant unit
  • Good performance status, ECOG 0 or 1.
  • Satisfactory blood tests: Hb \>10g/dl, neutrophiles \>1.0 (after any G-CSF), TRC \>75, Bilirubin\<2 x upper normal level, ASAT,ALAT\<5 x upper normal level, Creatinine \<1.25 x upper normal level. Albumin above lower normal level.
  • Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to GCP, and national/local regulations.
  • All patients should have received at least 8 weeks of chemotherapy.

Exclusion

  • Weight loss \>10% the last 6 months
  • Patient BMI \> 30
  • Previous diagnosed bone or CNS metastatic disease.
  • Previous diagnosed cancer mammae or malignant melanoma.
  • Palliative resection of primary CRC tumor.

Key Trial Info

Start Date :

June 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2028

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT02215889

Start Date

June 1 2014

End Date

June 1 2028

Last Update

February 6 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Oslo University Hospital

Oslo, Norway, 0424 Oslo